Trastuzumab Deruxtecan Redefines Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer: Insights from DESTINY-Breast05

Highlights

• Trastuzumab deruxtecan (T-DXd) reduced the risk of invasive disease recurrence or death by 53% compared to trastuzumab emtansine (T-DM1).
• The 3-year invasive disease-free survival (iDFS) rate was 92.4% for the T-DXd group versus 83.7% for the T-DM1 group.
• The benefit of T-DXd was consistent across key secondary endpoints, including disease-free survival and distant recurrence-free survival.
• Interstitial lung disease (ILD) remains a critical safety concern, occurring in 9.6% of patients treated with T-DXd, necessitating rigorous clinical monitoring.

The Unmet Need in Residual HER2-Positive Breast Cancer